KLRB1 and systemic lupus erythematosus: As shown in Fig 3A, α-GalCer enhanced the percentages of CD161+ iNKT subsets in controls (5.2±1.0% vs. 2.8±0.8%, p = 0.004) but not in SLE patients (1.8±0.3% vs. 1.5±0.3%, p = 0.304).